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1. Introduction 
Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) in 
adults. In the United States, almost half of patients entering ESRD programs were diabetic, 
and most of them (≥80%) had type 2 diabetes. This is due to the facts that 1) diabetes, 
particularly type 2, is increasing in prevalence; 2) diabetes patients now live longer; and 3) 
patients with diabetic ESRD are now being accepted for treatment in ESRD programs where 
formerly they had been excluded. The annual cost of caring for these patients, in the United 
States alone, exceeds $10 billion. The mortality rate of patients with diabetic nephropathy is 
high, and a marked increase in cardiovascular risk accounts for more than half of the 
increased mortality among these patients.  
The earliest clinical manifestation of renal involvement in diabetes is an increase in albumin 
excretion (microalbuminuria), a stage termed as incipient nephropathy at which renal 
histology may be relatively normal or may reveal glomerulosclerosis. Diabetes can cause a 
variety of pathological abnormalities: isolated glomerular basement membrane thickening, 
mesangial expansion, nodular intercapillary and/or diffuse glomeruloscelorsis or even 
advanced diabetic sclerosis. While glomerulopathy is quite the hallmark of diabetic 
nephropathy, the frequency and functional significance of interstitial lesions in diabetic 
kidney is now well recognized. Furthermore, the occurrence of non-diabetic glomerulopathy 
or vasculitis alone or superimposed on diabetic nephropathy is increasingly being 
documented in literature. The pathogenesis is incompletely understood and is very 
vigorously being investigated.  
Once overt diabetic nephropathy (proteinuria) is present, ESRD can be postponed, but in 
most instances not prevented, by effective antihypertensive treatment and careful glycemic 
control. Treatment options currently are limited to obvious pathogenic factors while several 
innovative therapies are under evaluation. Therefore, in the last decades, there has been 
intensive research into pathophysiologic mechanisms of early diabetic renal injury, 
predictors of diabetic nephropathy risk, and early intervention strategies 
2. Epidemiology 
Type 1 diabetes — The epidemiology of diabetic nephropathy has been best studied in 
patients with type 1 disease, since the time of clinical onset is usually known. About 0.5% of 
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the population in the United States and Central Europe has type 1 diabetes. The prevalence 
is higher in the northern Scandinavian countries and lower in southern Europe and Japan. 
Approximately 20 to 30 percent will have microalbuminuria after a mean duration of 
diabetes of 15 years (Orchard TJ 1990). Less than half of these patients will progress to overt 
nephropathy; microalbuminuria may regress or remain stable in a substantial proportion, 
probably related to glycemic and blood pressure control. 
Prior to the current period of intensive monitoring and treatment, it was suggested that 25 
to 45 percent of diabetic patients will develop clinically evident disease (the minimal 
criterion for which is a persistently positive urine dipstick for protein) (Parving HH, 1998). 
After so-called macroalbuminuria or clinical grade proteinuria (>300 mg albuminuria per 
day) develops, the majority of patients will progress to end-stage renal failure. 
 
 
Fig. 1. Estimated cumulative incidences of proliferative retinopathy or worse (A), 
nephropathy (B) and cardiovascular disease over time. 
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The overall incidence of end-stage renal disease (ESRD) was also substantial, with reported 
rates of 4 to 17 percent at 20 years from time of initial diagnosis and approximately 16 
percent at 30 years (Nathan DM 2009). A strong predictor of the development of ESRD was 
the level of glycemic control during the first two decades of IDDM. The risk of ESRD in the 
group with the poorest glycemic control was almost threefold higher than in the middle 
group, and fourfold higher than the group with the best glycemic control. 
In comparison to these findings, subsequent studies have found that the renal prognosis of 
type 1 diabetes, including the rate of progression to ESRD, has dramatically improved over 
the last several decades. In addition to the importance of glycemic control, more aggressive 
blood pressure reduction and the use of angiotensin converting enzyme inhibitors have 
been shown to reduce the rate of progression of, though not prevent, diabetic nephropathy 
(Krolewski M 1996). 
Type 2 diabetes is about nine times more prevalent than type 1 diabetes, accounting in part 
for the greater contribution of type 2 diabetic patients to ESRD incidence. In Caucasians, the 
prevalence of progressive renal disease has generally been lower in type 2 diabetes than in 
type 1 disease (Cowie CC, 1989). However, this observation may not apply to all groups with 
type 2 diabetes, some of whom have had a more ominous renal prognosis. Studies in type 2 
diabetic patients from Western Europe and in Pima Indians from Arizona showed rates of 
progression to nephropathy similar to those of type 1 diabetic patients. The risk of developing 
ESRD is much higher in black than in white American patients with type 2 diabetes.  
As previously described, however, the use of modern therapies lowers the incidence of ESRD, 
even in groups at extremely high risk such as the Pima Indians. In a subsequent study, for 
example, the incidence of diabetic ESRD was noted to have declined significantly from the 
period 1991-1994 to the period 1999-2002 (32 to 15 cases per 1000 patient-years, respectively). 
 
 
Fig. 2. Cumulative incidence of ESRD according to duration of IDDM and according to 
tertile of the index of hyperglycemia. Closed rectangles represent the tertile with the highest 
index of severe hyperglycemia; open triangles represent the middle tertile, and open circles 
represent the third with the lowest index of hyperglycemia. The differences among the 
curves are statistically significant, P = 0.017 
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Data suggest that the renal risk is currently equivalent in the two types of diabetes. Evidence 
in support of this hypothesis includes the observations in one report that the time to 
proteinuria from the onset of diabetes and the time to ESRD from the onset of proteinuria 
were similar in type 1 and type 2 disease (Ritz E, 1999). 
 
 
Fig. 3. Cumulative prevalence of persistent proteinuria among patients with type 1 or type 2 
diabetes according to the duration of diabetes (Panel A), and cumulative prevalence of renal 
failure among patients with type 1 or type 2 diabetes according to the duration of 
proteinuria (Panel B). 
Glycemic control, systemic blood pressure levels, and genetic factors seem to be very 
important in determining diabetic nephropathy risk. Other factors such as lipid levels, 
smoking habits, and vitamin D intake may also have a role in modulating this risk. 
As with type 1 diabetes, some patients with microalbuminuria due to type 2 diabetes, 
particularly those with good glycemic control, experience regression of microalbuminuria 
(Araki S, 2005) 
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3. Natural history and clinical course 
The course of renal involvement in type 1 diabetes can be divided in five stages. Stage I, 
present at diagnosis, is that of renal hypertrophy-hyperfunction. At this stage, patients at 
risk and not at risk of diabetic nephropathy cannot be clearly separated. A 25 to 50 percent 
elevation in the glomerular filtration rate (GFR) is seen early in the course in up to one-half 
of patients with type 1 diabetes mellitus, an abnormality that is exaggerated after ingestion 
of a protein load.  
 
 
Fig. 4. The five stages of renal involvement in type 1 diabetes 
This increase in GFR could be explained by a relative increase in glomerular capillary 
pressure and/or ultrafiltration coefficient. Glomerular hypertrophy and increased renal size 
typically accompany the rise in GFR. In an inception cohort study of adult-onset type 1 
diabetic subjects, a greater albumin excretion rate within the normal range, male gender, 
higher mean blood pressure and hemoglobin A1c, and shorter stature were independent 
predictors of development of microalbuminuria over 18 years of follow-up.  
Hyperfiltration also occurs early in the course of type 2 diabetes (Vora JP, 1992). The degree 
of hyperfiltration and the course of the GFR in type 2 diabetes mellitus was evaluated in 
more detail in a study of 194 Pima Indians of the Gila River Indian Community in Arizona 
who have the world’s highest incidence of Non-Insulin-Dependent Diabetes Mellitus 
(NIDDM) (Nelson RG, 1996). The following results were noted: 
 In 31 patients with a normal glucose tolerance test, the mean GFR was 123 mL/min 
 In 29 patients with impaired glucose tolerance, the mean GFR was 135 mL/min 
 In 30 patients with newly diagnosed type 2 disease, the mean GFR was 143 mL/min 
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 In 70 patients with overt diabetes for more than five years and either normal albumin 
excretion or microalbuminuria, the mean GFR was 153 mL/min; in 34 similar patients 
with overt proteinuria, the mean GFR was 124 mL/min 
 
 
Fig. 5. Glomerular filtration rate and effective renal plasma flow in non-insulin dependent 
diabetics (NIDDMs) (N= 110) and normal subjects (N = 32). 
After four year follow-up, the GFR rose 14 percent in patients with impaired glucose 
tolerance, 18 percent in newly diagnosed patients, was stable in those with 
microalbuminuria, and fell 35 percent in those with overt proteinuria. This pattern is 
consistent with the hypothesis that hyperfiltration causes progressive glomerular damage. 
However, the base-line glomerular filtration rate in the diabetic subjects predicted neither 
increasing urinary albumin excretion nor declining glomerular filtration during four years 
of follow-up, suggesting that hyperfiltration itself is not the principal factor in the 
development or progression of nephropathy. Higher urinary albumin excretion at base line, 
however, did predict increasing albuminuria and, in subjects with macroalbuminuria, 
declines in the GFR; these findings suggest that enhanced protein flux across the glomerular 
capillary wall contributes to progressive glomerular damage. Proteinuria also predicts the 
progression of renal disease in patients with nondiabetic renal disease. 
Studies in experimental animals indicate that dilatation of the afferent (precapillary) 
glomerular arteriole plays an important role in the hyperfiltration response, by raising both 
the intraglomerular pressure and renal blood flow. (Bank N, 1991) A role for hormones is 
suggested by the ability of a chronic infusion of a somatostatin analogue octreotide to 
partially reverse both the early hyperfiltration and the increase in renal size in type 1 
diabetic patients (Serri O, 1991). There was, however, a fall in the plasma concentration of 
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insulin-like growth factor I (IGF-1), which is produced in part within the kidney. Although 
the pathogenetic role of IGF-1 is unproven, it is of interest that infusion of this hormone in 
normal subjects can replicate the findings seen in diabetics — renal vasodilatation and an 
elevation in GFR. Similar hemodynamic changes plus renal hypertrophy can be induced by 
IGF-I in experimental animals.  
 
 
Fig. 6. Changes in the Mean Glomerular Filtration Rate and Median Urinary Albumin-to-
Creatinine Ratio from Base Line to the End of Follow-up in Subjects with Impaired Glucose 
Tolerance (IGT), Newly Diagnosed Non-Insulin-Dependent Diabetes Mellitus  
(New NIDDM), NIDDM and Normal Urinary Albumin Excretion (Normoalbuminuria), 
NIDDM and Microalbuminuria, and NIDDM and Macroalbuminuria. 
Each arrow connects the value at the base-line examination and the value at the end of 
follow-up. The dashed line indicates the time of diagnosis, and the shaded area the 25th 
through 75th percentiles of values in subjects with normal glucose tolerance. Albumin was 
measured in milligrams per liter and creatinine in grams per liter. 
Several other factors directly related to hyperglycemia also may be important, including the 
intracellular accumulation of sorbitol and the formation of glycosylated proteins (Passariello 
N, 1993). The enzyme aldose reductase converts intracellular glucose to sorbitol, which then 
accumulates within the cells. Studies in hyperfiltering humans with type 1 diabetes have 
shown that the chronic administration of an aldose reductase inhibitor (tolrestat) lowers the 
GFR toward normal. 
Stage II is defined by the presence of detectable glomerular lesions in patients with normal 
albumin excretion rates and normal blood pressure levels. Normoalbuminuric patients with 
more severe glomerular lesions might be at increased risk of progression. Patients can 
remain in stage 2 for the remainder of their lives. However, those in whom nephropathy is 
destined to progress further will at this stage exhibit a loss of the normal nocturnal blood 
pressure decline (i.e., night/day ratios >0.9 and non-dipping) as an early diabetic 
nephropathy indicator that often precedes the development of persistent microalbuminuria. 
Microalbuminuria, typically occurring in 2 to 5 percent of patients per year, defines stage 
III. Patients with microalbuminuria are referred to as having incipient nephropathy. 
Microalbuminuria (a sign of endothelial dysfunction that is not necessarily confined to the 
kidney) may be present earlier, particularly during adolescence and in patients with poor 
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glycemic control and high-normal blood pressure levels. Compared with normoalbuminuric 
patients, patients with persistent microalbuminuria have threefold to fourfold greater risk of 
progression to proteinuria and ESRD. Current studies indicate that between 20% and 45% of 
microalbuminuric type 1 diabetic patients will progress to proteinuria after about 10 years of 
follow-up, whereas 20% to 25% will return to normoalbuminuric levels (Hovind P, 2004) 
and the rest will remain microalbuminuric. At this stage, glomerular lesions are generally 
more severe than in the previous stages, and blood pressure tends to be increasing, often 
into the hypertensive range. Other laboratory abnormalities, such as increased levels of 
cholesterol, triglycerides, fibrinogen, Von Willebrand’s factor, and prorenin, can be detected 
in some patients. Diabetic retinopathy, lower extremity amputation, coronary heart disease, 
and stroke are also more frequent in this group.  
The normal rate of albumin excretion is less than 20 mg/day (15 µg/min); persistent 
albumin excretion between 30 and 300 mg/day (20 to 200 µg/min) is called 
microalbuminuria and, in patients with type 1 diabetes, persistent microalbuminuria may be 
indicative of early diabetic nephropathy unless there is some coexistent renal disease. 
It was initially thought that microalbuminuria precedes the loss of glomerular filtration rate 
(GFR) in patients with type 1 diabetes. However, some patients with normoalbuminuria or 
microalbuminuria have significant reductions in GFR prior to the development of 
macroalbuminuria. Loss of renal function, which was defined as an estimated decrease in 
GFR of more than 3.3 percent per year, occurred in 9 percent of patients with 
normoalbuminuria and 16 percent with regression of microalbuminuria. Loss of renal 
function occurred much more frequently (32 and 68 percent) in patients with stable or 
progressive microalbuminuria, respectively. 
Patients with newly diagnosed type 2 diabetes in which 6.5 percent had microalbuminuria 
and 0.7 percent had macroalbuminuria at the time of diagnosis. The rate of 
microalbuminuria at the time of diagnosis of type 2 diabetes may be higher in older patients. 
There are at least two possible explanations for the presence of microalbuminuria at the time 
of diagnosis of type 2 diabetes: the patients had previously undiagnosed diabetes or some 
other disease was responsible for the microalbuminuria. Forty to 50 percent of patients with 
type 2 diabetes who have microalbuminuria eventually die of cardiovascular disease; this is 
three times as high a rate of death from cardiac causes as among patients who have diabetes 
but have no evidence of renal disease. 
As with type 1 diabetes, some patients with microalbuminuria and type 2 diabetes regress to 
normoalbuminuria. At six years, regression occurred in 51 percent, while progression to 
macroalbuminuria occurred in 28 percent. Several factors (short duration of microalbuminuria, 
better glycemic and blood pressure control, and the use of ACE inhibitors or angiotensin II 
receptor blockers) were independently associated with remission. 
Stage IV occurs after 10 to 20 years of diabetes and is characterized by the presence of 
dipstick-positive proteinuria: proteinuria of greater than 300 mg/d. Hypertension is present 
in about 75% of these patients, and reduced GFR and dyslipidemia are also common. 
Retinopathy and peripheral and autonomic neuropathy are present in most patients. In 
addition, the risk for cardiovascular events is extremely high, and asymptomatic myocardial 
ischemia is frequent. Without therapeutic interventions, GFR declines by about 1.2 
mL/min/month in proteinuric type 1 diabetic patients. In type 2 diabetic patients, Once 
macroalbuminuria is present, creatinine clearance declines at a rate that varies widely from 
patient to patient; the average reduction is 10 to 12 ml per minute per year in untreated 
patients. Hypertension and proteinuria may accelerate the decline in the glomerular 
filtration rate and the progression to end-stage renal disease. 
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Progression to ESRD (stage V) occurs 5 to 15 years after the development of proteinuria. 
Renal replacement therapy—either dialysis or transplantation is required at this stage. 
4. Pathogenesis 
Diabetic nephropathy occurs as a result of a complex yet incompletely understood interaction 
between hemodynamic and metabolic factors (Cooper, M., 2001). Hemodynamic factors that 
contribute to the development of diabetic nephropathy include increased systemic and 
intraglomerular pressure, as well as activation of vasoactive humoral pathways including the 
renin angiotensin system and endothelin (G.M. Hargrove, 2000). These hemodynamic 
pathways activate intracellular second messengers such as protein kinase C (PKC), Mitogen-
activated protein (MAP kinase) (M. Haneda, 1997), nuclear transcription factors such as NF-kB 
and various growth factors such as the prosclerotic cytokine, TGF-ǃ and the permeability 
enhancing growth factor, vascular endothelial growth factor, VEGF.  
Glucose dependent pathways are also activated within the diabetic kidney and result in 
enhanced oxidative stress, renal polyol formation (Dunlop ME, 2000) and the accumulation 
of advanced glycation end products (AGEs). In combination, these pathways ultimately lead 
to increased renal albumin permeability and extracellular matrix accumulation, resulting in 
increasing proteinuria, glomerulosclerosis and ultimately tubulointerstitial fibrosis. 
5. Hemodynamic pathways 
Glomerular hyperperfusion and hyperfiltration are the early signs resulting from decreased 
resistance in both the afferent and efferent arterioles of the glomerulus. Afferent arteriole 
seems to have a greater decrease in resistance than the efferent, which in fact may have 
increased resistance. Many factors have been reported to be involved in this faulty 
autoregulation, including nitric oxide, prostanoids, vascular endothelial growth factor 
(VEGF), TGF-ǃ1, and the renin angiotensin system, specifically angiotensin II. These early 
hemodynamic changes predispose to albumin leakage from the glomerular capillaries and 
overproduction of mesangial cell matrix, as well as thickening of the glomerular basement 
membrane and injury to podocytes (Ziyadeh, F 2008). In addition, increased mechanical 
strain from these hemodynamic changes can induce localized release of certain cytokines 
and growth factors (Wolf, G.F.N, 2007) 
 
 
Fig. 7. Interaction of hemodynamic and metabolic pathway, cytokines and intracellular 
signaling molecules mediating diabetic nephropathy 
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The action of vasoactive hormones, such as angiotensin II and endothelin are mediator of 
renal hemodynamic changes. Glomerular hypertension and hyperfiltration contribute to the 
development of diabetic nephropathy because use of renin–angiotensin blockers preserves 
kidney function and morphology. Blockade of the renin-angiotensin–aldosterone system 
antagonizes the profibrotic effects of angiotensin II by reducing its stimulation of TGF-ǃ1 
(Hilker, KF, 2005). Support that such profibrotic effects underlie diabetic nephropathy has 
also been provided by study of an animal model of diabetic nephropathy (Nagai Y, 2005). 
Transient blockade of the renin–angiotensin system (for 7 weeks) in prediabetic rats reduced 
proteinuria and improved glomerular structure. Additionally, the administration of an 
angiotensin converting-enzyme inhibitor to patients with type 1 diabetes and nephropathy 
appears to reduce serum concentrations of TGF-ǃ1. A correlation exists between decreased 
levels of TGF-ǃ1 in serum and urine and renal protection, as determined by changes in the 
glomerular filtration rate. 
5.1 Renin-angiotensin system in diabetic nephropathy 
The renin-angiotensin system (RAS) has been extensively studied in diabetes. Earlier studies 
centered on the systemic RAS, and the data obtained have been conflicting, with 
stimulation, suppression, and no change in the system being reported (Wolf, G, 2007). The 
factors that influence the systemic RAS in addition to the different stages of disease and 
species studied may explain many of these divergent findings. However in various diabetic 
models, increased renal renin content relative to plasma renin levels has generally been 
found, thus suggesting impaired renal renin release into the circulation. In clinical diabetic 
nephropathy, there is decreased plasma rennin activity that may be due to nonenzymatic 
glycation of prorenin with decreased conversion to active renin. Thus, diabetic nephropathy 
has traditionally been considered a “low renin” state. However, plasma renin activity may 
not accurately reflect activity of the RAS in the kidney. 
Another problem has been the difficulty of accurate measurement of plasma angiotensin-II 
(Ang II), which is an important issue because discordance can exist between plasma renin 
and Ang II levels. More recently, the intrarenal RAS has been the focus of extensive study. 
Abundant evidence indicates the existence of local tissue RASs that are regulated 
independent of plasma RAS (Ballerma, B.J., 1984). It was reported that glomerular Ang II 
receptors decrease in the diabetic rat 3 to 4 weeks after induction of the disease. 
Downregulation of glomerular Ang II receptors implies that intra- renal Ang II generation 
may be increased. The density of Ang II receptors in the proximal tubules was reported to 
be reduced in diabetic rats and was accompanied by decreased mRNA expression for the 
AT1 receptor (Cheng, H.F, 1994). Recently, AT1 receptor density has also been shown to be 
decreased in mesangial cells when incubated in high-glucose media (Amiri F, G, 1999). ACE 
activity in whole kidney is low in diabetes. 
However, this is probably due primarily to mesangial RAS. Staining for ACE has been 
found to be enhanced in glomeruli and vasculature of diabetic rats and in patients with 
diabetic nephropathy (Mizuiri, S., 1998). These data suggest that the term “intrarenal” RAS 
is oversimplistic, in as much as the vascular RAS (vessels and glomeruli) appears to be 
regulated differently from the tubulointerstitial RAS. Angiotensin receptor blockers (ARBs) 
enhance the renal vasodilation in patients with diabetes (despite the presence of low plasma 
rennin activity), again supporting the concept that the renal vascular RAS is activated in 
several intrarenal compartments including the glomeruli by several orders of magnitude 
higher than those found systemically. This shows the existence of both local RAS acting is 
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independently of the systemic RAS and also is consistent with the finding that in most renal 
cell culture studies, effects of Ang II are observed at substantially higher concentrations 
(about 0.01-1.0 mmol/L) than those found in the systemic circulation. 
5.2 Vaso-active hormones 
Endothelium is an interior covering of blood vessels. There are various biological functions 
of endothelium and it regulates vascular tone and maintains free flow of blood in vessels 
(Escandon, J.C, 2001). The luminal surface of every blood vessel, forms a physical and 
metabolic barrier to circulating elements. The endothelium is an important endocrine organ 
and releases a number of vasoactive hormones, including endothelin (ET-1) (Ulker, 2003), 
endothelium-derived hyperpolarizing factor (EDHF: nitric oxide and prostacyclin). 
Endothelin-1 is a potent vasoconstrictor, Endothelium-derived hyperpolarizing factor is still 
a controversial subject of vascular biology. Endothelial cells of every blood vessel release 
nitric oxide and prostacyclin and they form a particular partnership in the regulation of 
vascular and platelet function. 
5.3 Nitric Oxide 
Nitric Oxide (NO), originally identified as “endothelial derived relaxing factor,” is a 
ubiquitously utilized signaling molecule that regulates a wide variety of organ and cellular 
functions, including renal hemodynamics and salt and water regulation. NO is generated 
enzymatically from the amino acid L-arginine by one of three specific nitric oxide synthases: 
“neuronal”(NOS1 or nNOS), “endothelial” (NOS3 or eNOS), or “inducible” (NOS2 or 
iNOS). Many, but not all, of the intracellular signaling pathways activated by NO are 
mediated by activation of guanylate cyclase, which increases intracellular levels of cyclic 
guanosine monophosphate. 
All three NOS isoforms are present in the mammalian kidney, with both distinct and 
overlapping patterns of distribution. In normal kidney, NOS1 is highly expressed in the 
macula densa and glomerular parietal epithelium, as well as in the medulla in the collecting 
ducts and thin ascending limb. NOS2 is expressed in the endothelium of glomerular 
capillaries and afferent and efferent arterioles, renal arteries, and descending vasa recta, as 
well as in proximal tubule and medullary thick ascending limb. NOS3 is also expressed in 
tubules, including S3 segments of the proximal tubule, medullary thick ascending limb, and 
collecting duct, in addition to arcuate arteries and vasa recta bundles (Kone, BC, 1997). Both 
in vivo and in vitro studies have provided conflicting results regarding NOS expression and 
NO production in diabetes. Most but not all studies in cultured renal cells have determined 
decreased NO production in response to hyperglycemia (Komers R, 2003).  
It has been established for a long time that the principal risk factors that affect the 
development and progression of diabetic nephropathy includes uncontrolled 
hyperglycemia, hypertension (systemic and glomerular) and activation of RAAS. All these 
three factors have been shown to modulate intra renal NO generation either directly or 
through signaling pathways. The role of NO in affecting the renal structure and function is 
very complicated and depends on several factors including the stage of diabetic renal 
disease, isoforms of NOS involved, structures in the kidney, and influence of other factors in 
diabetic milieu. The complex metabolic milieu in diabetes triggers several 
pathophysiological mechanisms that simultaneously stimulate and suppress intrarenal NO 
production. The net effect on renal NO levels depends on the mechanisms that prevail in a 
given stage of the disease process.  
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5.3.1 Dual role of Nitric Oxide in diabetic nephropathy 
The currently available evidence enables us to reasonably conclude that early diabetic 
nephropathy is associated with increased renal NO production mediated primarily by 
constitutively released NO through eNOS or NOS III activation. There is some contribution 
to this augmented NO production through nNOS (NOS I) derived enhanced synthesis, 
particularly from macula densa region of the kidney. Together the increased intrarenal NO 
generation contributes to the development of glomerular hyperfiltration and 
microalbuminuria that characterize early diabetic nephropathy.  
On the other hand, advanced diabetic nephropathy with severe proteinuria, hypertension 
and renal failure is associated with a state of progressive NO deficiency. As the duration of 
diabetic state increases, factors that suppress NO bioavailability prevail. Many factors 
including activation of protein kinase C, activation of TGF-beta, NO quenching by advanced 
glycosylation end products (AGE) contribute to the NO deficient state – either directly or by 
inhibiting and/or by post translational modification of activity of NOS isoforms. Other 
inhibitors of NOS enzyme such as asymmetric dimethylarginine (ADMA) accumulate in 
diabetic nephropathy and may contribute to progression of DN and such association has 
also been observed in other microvascular complications such as retinopathy. Most of these 
changes are mediated by endothelial and partly inducible NOS in the chronic advanced 
stage of DN. Progressive loss of renal parenchyma also contributes partially to the NO 
deficiency since kidney is a major source of L-arginine, the sole precursor of NO. These 
changes and the factors affecting them are discussed well in a review (Prabhakar 2005) and 
schematically represented in the figure below. 
 
RENAL NITRIC OXIDE PRODUCTION IN DIABETIC NEPHROPATHY
Diabetic Nephropathy
Early nephropathy Advanced nephropathy
Microalbuminuria
Hyperfiltration
Declining GFR
Increasing proteinuria
Glomerulosclerosis
Renal NO production
Insulin
Shear stresses 
VEGF
eNOS, nNOS,?iNOS
AGE formation
Oxidative stress
Hyperglycemia
eNOS, iNOS
NO Quenching
Angiotensin II
TGF- , PKC 
 
Fig. 8. Role of Nitric Oxide in Diabetic Nephropathy 
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In a recent study, the natural history of renal manifestations have been described in ZSF1 rats, 
a recently developed rodent model of type 2 diabetes who developed obesity and 
hyperglycemia by 20 weeks of age on a high-carbohydrate diet. They also developed systolic 
and diastolic hypertension, hypercholesterolemia, profound hypertriglyceridemia, proteinuria, 
and renal failure. Renal histology demonstrated changes consistent with early diabetic 
nephropathy, including arteriolar thickening, tubular dilation and atrophy, glomerular 
basement membrane thickening, and mesangial expansion. Furthermore, renal nitric oxide 
production was decreased, and homogenates from renal cortices demonstrated reduced 
expression of renal endothelial and inducible nitric oxide synthases. These changes were 
associated with increased urinary levels and renal expression of 8-hydroxydeoxyguanosine, an 
indicator of mitochondrial oxidative stress, as well as with increased renal peroxynitrite 
formation. Administration of either insulin or the antioxidant alpha-lipoic acid decreased 
proteinuria and oxidative stress, but only the former slowed progression of renal failure 
(Prabhakar 2007). 
5.4 Prostacyclin 
The first step in prostacyclin synthesis is the liberation of arachidonic acid from membrane-
bound lipids via the enzymatic actions of phospholipase A2 (PLA2). In endothelial cells, 
phospholipase A2 activation is a calcium-dependent step. Once liberated, arachidonic acid is 
available for metabolism by cyclooxygenase (COX). Cyclooxygenase is present in two 
isoforms: COX-1 and COX-2. Cyclo-oxygenase-1, like NOSI or NOSIII, is constitutively 
expressed, while COX-2, like NOSII, is induced at sites of inflammation and/or by PAMPs. 
In healthy endothelial cells, COX-1 is the predominate isoform. Cyclooxygenase has two 
enzymatic activities: firstly, an oxygenase step forms prostaglandin (PG) G2; and secondly, a 
peroxidase step, which forms PGH2 from PGG2. Prostaglandin H2 is the substrate for a 
range of downstream prostaglandin synthase enzymes, including prostacyclin synthetase 
(PGIS), the actions of which result in the formation of prostacyclin. Endothelial cells are 
enriched in cyclooxygenase-1(COX-1) and PGIS, which is why, when phospholipase A2 is 
activated, prostacyclin is the predominant metabolite made. It is important to note that in 
platelets, which also express predominantly COX-1, thromboxane is the principal product 
made. This is because platelets express mainly thromboxane synthase with negligible levels 
of PGIS. 
5.5 Endothelin1 
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide produced by vascular endothelium 
from big ET-1 (Xu 1994) via specific cleavage by endothelium converting enzyme (ECE). ET-
1 produces its actions by acting on endothelin ETA and ETB receptors (Haynes, 1993). ETA 
receptor predominates in vascular smooth muscle cells and mediates vasoconstriction in 
both large and small blood vessels where as ETB receptors on endothelial cells mediate 
vasodilation through the production of nitric oxide and prostacyclin (Verhaar, MC, 1998). 
ET-1 is involved in the pathogenesis of cardiovascular disorders such as hypertension and 
heart failure including diabetic nephropathy (Benigni 1998). Diabetes mellitus induces the 
renal overexpression of ET-1 in the glomeruli and tubular epithelial cells leading to 
progression of diabetic nephropathy. It was shown that diabetes-induced elevated level of 
renal ET-1 might induce glomerular hyperperfusion and damage tubulointerstitium in rats. 
The diabetes-induced elevated level of renal ET-1 was noted to accelerate the progression of 
diabetic nephropathy in rats31. It has been documented that ET-1 activates a variety of 
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signaling systems to induce contraction, hypertrophy, proliferation, and extracellular matrix 
accumulation in mesangial cells (Sorokin, 2003). The detrimental role of ET-1 in 
pathogenesis of diabetic nephropathy has been confirmed by the fact that diabetes induced 
elevated level of renal ET-1 is associated with an expansion of mesangial cells and collagen 
deposition in the glomeruli of diabetic mice. It has been recently demonstrated that ET-1 
mediated activation of ETA receptor induced the renal TGF-ǃ production and inflammation 
in diabetic rats (Sasser, 2007). Treatment with CPU0213, a dual ETA/ETB receptor 
antagonist has been found to improve the renal function in rats with diabetic nephropathy 
by suppressing Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 
suggesting that ET-1 contributes to the pathogenesis of diabetic nephropathy via 
upregulation of NADPH oxidase mediated ROS production in renal cells (Xu, M., 2009). 
Thus under pathological conditions, prevention of endothelin-mediated various signaling 
pathways may provide an alternative approach to treat diabetic nephropathy. 
5.6 Urotensin 
Urotensin II (UII) is an 11-amino acid vasoactive peptide, recently identified as the ligand 
for a novel G protein-coupled receptor, GPR-14 (renamed urotensin receptor [UT]). In 
addition to its potentvasoconstrictive actions, UII also has trophic and profibrotic effects, 
leading to its implication in the pathogenesis of heart failure. However, it has been noted 
that elevated plasma levels of UII in association with renal impairment and diabetes and 
diabetic nephropathy. Urotensin-II, an endogenous vasoconstrictor, has been suggested to 
be involved in the pathogenesis of vascular endothelial dysfunction (VED) (Maguire, J.J., 
2002). Urotensin-II increases the activity of NADPH oxidase and plasminogen activator 
inhibitor-1 (PAI-1) and cause decrease in endothelium dependent relaxation (Watanabe, T., 
2006). The overexpression of urotensin-II in endothelial cells cause VED by increasing the 
expression of type 1 collagen and formation of ROS. 
6. Metabolic pathway 
Advanced glycosylation end products or AGEs are a chemically heterogeneous group of 
compounds formed as a result of the ‘‘Maillard reaction’’ when reducing sugars react non-
enzymatically with amine residues, predominantly lysine and arginine, on proteins, lipids 
and nucleic acids. While the initial stage of the reaction leading to the formation of 
reversible glycosylation proteins termed Schiff bases is rapid and glucose dependent, a 
much slower reaction over a period of days results in the formation of the more stable 
Amadori product. These early glycosylation products accumulate predominantly on long 
lived proteins such as vessel wall collagen and crystallines (Brownlee, 2001), undergoing a 
series of in vivo rearrangements to form irreversible, complex compounds and cross-links, 
termed AGEs.  
Once AGE related cross‐links form on proteins, they become resistant to proteolytic 
degradation (Thomas, 2005). As well as their non-receptor mediated effects; AGES can exert 
their biological effects through receptor-mediated mechanisms, the most important of which 
is the receptor for advanced glycation end products (RAGE). RAGE is a signal transduction 
receptor that belongs to the immunoglobin superfamily and is expressed on a number of cell 
types including monocytes/macrophages, endothelial cells, renal mesangial cells and 
podocytes (Yan, S.F., 2004). Binding of AGEs to the RAGE receptor activates a number of 
pathways implicated in the development of diabetic complications, specifically diabetic 
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renal disease. These include enhanced cytosolic reactive species formation, stimulation of 
intracellular molecules such as PKC and NF-kB and the activation and expression of a 
number of growth factors and cytokines such as TGF-ǃ and VEGF (Wendt, T., 2003). Indeed, 
strategies to inhibit the formation of AGEs have been shown to ameliorate diabetic 
nephropathy. 
In the initial study by Soulis-Liparota et al. aminoguanidine, an inhibitor of AGE formation, 
which acts by scavenging intermediates in the advanced glycation pathway attenuated the 
rise in albuminuria observed in diabetic rodents, while preventing increases in collagen 
related fluorescence in isolated glomeruli and renal tubules (Soulis-Liparota, T. 1991). 
Similar results have been obtained with alagebrium, a putative AGE cross-link breaker. In 
an experimental study, both aminoguanidine and alagebrium attenuated the albuminuria 
observed in diabetic rodents (Forbes, J.M., 2003). Furthermore, alagebrium was also 
beneficial when used as part of a delayed intervention protocol, suggesting that it may be 
useful in both preventing and retarding diabetic nephropathy (Ziayadeh, F.N., 1991).  
A subsequent study confirmed and extended these findings. The early (weeks 16–32) and 
late (weeks 24–32) administration of alagebrium was again shown to reduce albuminuria in 
a type 1 diabetic rodent model. As a number of previous groups had demonstrated increases 
in collagen and other extracellular matrix components in experimental diabetic 
nephropathy, this study also sought to determine the mechanisms surrounding the 
improvements in microalbuminuria in diabetic rodent kidneys. The compound was shown 
to reduce diabetes induced increases in the gene expression of TGF-ǃ1, connective tissue 
growth factor (CTGF) and collagen IV. Early treatment with alagebrium was also associated 
with significant structural improvement in the kidney including a reduction in the 
glomerulosclerotic index and tubulointerstitial area, in conjunction with a reduction in AGE 
peptide fluorescence in serum and the kidney. Furthermore, a reduction in renal 
accumulation of the specific AGE, carboxymethylysine (CML) and decreased RAGE 
immunostaining was also seen, providing further evidence that accumulation of AGEs is 
implicated in renal extracellular matrix accumulation in diabetes.  
In the setting of diabetes mellitus and long-term hyperglycemia, nonenzymatic modification 
of proteins (or lipids) by glucose, or its metabolic products, results in their stable 
modification and altered function. This process is thought to underlie a major pathogenic 
pathway leading to tissue injury in diabetes. A major pathway for AGE formation involves 
triose phosphate intermediaries derived from metabolism of glucose. Triose phosphates 
build up as intracellular glucose increases and can nonenzymatically form the early 
glycosylation product methyglyoxal by spontaneous decomposition (Degenhardt 1998 and 
Frye 1998). Amine-catalyzed sugar fragmentation reactions then modify protein lysine 
residues directly, forming N- (epsilon) - (carboxymethyl) lysine (CML), a major product of 
oxidative modification of glycated proteins. Alternatively, reaction of terminal amino 
groups (e.g., on lysine) with glucose itself may form from early glycation products (i.e., 
Amadori products) that rearrange to produce stable moieties that possess distinctive 
chemical crosslinking and biologic properties, designated AGEs (Cohen 2003 and Vlassara 
1981). Other glucosederived Amadori products and fructose are thought to be potential 
precursors of 3-deoxyglucosone (3-DG) in vivo. Fructose generated by the aldose reductase 
pathway is converted into fructose-3- phosphate by the action of 3-phosphokinase (3- PK). 
This leads to the generation of 3-deoxyglucosone, a central precursor in the generation of an 
array of AGEs, in particular, CML-adducts and others (3-Deoxyglucosone, 1999) 3-DG can 
further react with proteins to form pyrrolines or pentosidine.  
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AGEs have been suggested to represent a general marker of oxidative stress and long‐term 
damage to proteins in aging, atherosclerosis, and diabetes (Wendt T.M., 2003). Renal CML-
AGE is increased in diabetes. Immunolocalization of CML in skin, lung, heart, kidney, 
intestine, intervertebral discs, and particularly in arteries provide evidence for age-
dependent increases in CML accumulation in distinct locations, and acceleration of this 
process in diabetes (Schleicher, E.D., 1997). Immunostaining and immunoblots of diabetic 
human kidneys show increased CML in diabetic glomeruli, especially in the mesangial 
matrix and capillary walls (Nathan, D.M., 2005). 
6.1 Oxidative stress 
Generally, large amount of reactive oxygen species are generated with in nephron by 
metabolic activity that is counter balanced by a large number of antioxidant enzymes and 
free radical scavenging systems. Peroxidation of cell membrane lipids, oxidation of proteins, 
renal vasoconstriction and damage to DNA are the negative biological effects of reactive 
oxygen species. Unfortunately, hyperglycemia tips the balance towards production of 
reactive oxygen species, most of which seem to be generated in the mitochondria 
(Nishikawa, T. 2007). The metabolism of glucose through destructive alternate pathways, 
such as via PKC activation and advanced glycation end‐product formation, in the setting of 
hyperglycemia also seems partly dependent on reactive oxygen species. Oxidative stress 
specifically induced by hyperglycemia even before diabetes becomes clinically apparent. 
DNA damage marker induced by reactive oxygen species is higher in patients with severe 
nephropathy (i.e. proteinuria versus microalbuminuria). Diabetic nephropathy is linked 
with severe oxidative stress. This pathway may be responsible for the decreased 
bioavailability of nitric oxide in the kidney (Prabhakar 2007). 
6.2 Reactive oxygen species 
Diabetic nephropathy is characterized by excessive deposition of extracellular matrix (ECM) 
in the kidney, leading to glomerular mesangial expansion and tubulointerstitial fibrosis. 
Clinical studies have demonstrated that high blood glucose is the main cause of initiation 
and progression of diabetic vascular complications including nephropathy. High reactive 
oxygen species (ROS) induced by glucose upregulates TGF-ǃ1 and extra cellular matrix 
protein (ECM) expression in the glomerular mesangial cells. Hyperglycemia induced ROS 
generation and ROS-activated signal transduction cascade and transcription factors and 
overexpression of genes and proteins in glomerular mesangial and tubular epithelial cells 
lead to ECM accumulation in diabetic kidney. 
6.3 Nephrin 
Podocytes (specialized visceral epithelial cells) are important for the maintenance of the 
dynamic functional barrier (Mundel 2002). Nephrin, a protein found in these cells, is crucial 
for maintaining the integrity of the intact filtration barrier. The renal expression of nephrin 
might be impaired in diabetic nephropathy. Patients with diabetic nephropathy have 
markedly reduced renal nephrin expression and fewer electron‐dense slit diaphragms 
compared with patients without diabetes and minimal nephropathic changes or controls 
(Benigni. 2004). Furthermore, nephrin excretion is raised 17-30% in patients with diabetes 
(with and without albuminuria) compared with that in individuals without diabetes.  
Thus, nephrin excretion could be an early finding of podocyte injury, even before the onset 
of albuminuria (Kobayashi, 2006). Treatment with blockers of the renin-angiotensin-
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aldosterone system might help protect nephrin expression. In a study of patients with type 2 
diabetes, treatment with an angiotensin-converting-enzyme inhibitor for 2 years maintained 
nephrin expression at control levels compared with that in untreated patients with diabetes. 
By contrast, the expression of two other important podocyte and slit diaphragm proteins, 
podocin and CD2AP, was similar in the three groups. Comparable decreases in renal 
nephrin expression were reported in other studies of diabetic nephropathy. 
6.4 Vitamin D 
Vitamin D has a role beyond the regulation of calcium metabolism. There is evidence that 
the vitamin D system is also involved in regulation of the immune system, cell growth, and 
differentiation. Vitamin D binds to its nuclear receptor, and later to the vitamin D response 
element of target genes, to regulate gene transcription. It also interacts with pathways that 
are germane to the development and progression of diabetic complications, including the 
renin–angiotensin system (RAS), hypertension, inflammation, and albuminuria. Three 
recent randomized trials have shown that the vitamin D analogue—19-nor-1-ǂ-
dihydroxyvitamin D2 (paricalcitol) can reduce proteinuria in patients with chronic kidney 
disease, including those with diabetes.  
 
 
ACE=angiotensin-converting enzyme.  
AT1=type 1 angiotensin receptor. 
PRR=(pro)renin receptor.  
ACE2=angiotensin-converting enzyme 2. TACE=tumor necrosis factor ǂ converting enzyme. mas-
1=receptor for angiotensin 1–7. 
Fig. 9. Interactions between vitamin D and key elements of the renin–angiotensin system 
Vitamin D is a negative regulator of RAS (Li YC, 2002). In experimental chronic kidney 
disease, paricalcitol reduces the renal expression of renin, the (pro)renin–receptor, 
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angiotensinogen, and the type 1 angiotensin receptor (Freundlich M, 2008). Vitamin D also 
inhibits tumor necrosis factor ǂ converting enzyme (TACE) (Dusso A, 2010), which 
regulates the shedding of angiotensin-converting enzyme 2 (ACE2), itself the major enzyme 
that metabolizes angiotensin II in the proximal tubule. Diabetes is associated with reduced 
ACE2 expression; therefore inhibition of TACE expression might improve the balance of 
RAS in the kidney, and might have additional renoprotective effects by inhibition of the 
TACE-dependent release of other pathogenic mediators. 
Vitamin D has several anti-inflammatory actions, including effects on prostaglandin 
synthesis, inhibition of nuclear factor κB signaling, and innate immunity, all of which have 
been implicated in diabetic chronic kidney disease. Vitamin D deficiency is associated with 
raised concentrations of C-reactive protein. In previous studies, paricalcitol reduced C-
reactive protein concentrations in patients with chronic kidney disease, which paralleled the 
decline in albuminuria 
Patients with diabetes have increased rates of vitamin D deficiency (Tanaka H, 2009) 
especially in those with chronic kidney disease in whom the urinary loss of protein-
associated vitamin D magnifies reduced activation of vitamin D by the proximal tubule, and 
reduced expression of the vitamin D receptor. For these patients, it seems rational to replace 
vitamin D. Selective analogues that restore vitamin D receptor signaling without risking 
hypercalcemia or hyperphosphatemia might have particular advantages, because of the 
aberrant calcification of diabetic vessels. Of note, vitamin D replacement reduced 
proteinuria in about half of diabetic patients with stage 3 or 4 chronic kidney disease in a 
placebo-controlled trial (Teng M 2003) 
7. Histopathology 
The pathogenesis of diabetic nephropathy is complex, and renal pathological lesions are 
diverse. Most likely, there are many pathogenic pathways, which through composite, 
interactive routes lead to the histological damage that we see in renal biopsies of patients 
with diabetic nephropathy (Elisabeth J.J, 2011). Though the number of patients with type 2 
diabetes in a worldwide context is increasing and is predicted to be 438 million in 2030, 
paradoxically, diabetic nephropathy is probably becoming the renal disease per se for which 
the least renal biopsies are performed. In many centers, clinical parameters in the absence of 
a renal biopsy will diagnose the patient with diabetic nephropathy. Only if unusual signs or 
symptoms are present, such as sudden onset nephrotic syndrome, will a renal biopsy be 
performed, mostly with the aim to exclude other causes than diabetic nephropathy for the 
patient’s clinical presentation. This means that in relation to diabetic nephropathy, co-
morbidity is often seen by the pathologist in the renal biopsy, and cases in which diabetic 
nephropathy alone is present become less frequent. In many recent publications, the 
diagnosis of diabetic nephropathy was based on clinical symptoms, which, in many studies, 
also formed the gold standard on the evaluation of intervention therapies meant to prevent, 
slow down, or even reverse the processes causing diabetic nephropathy. 
7.1 Histopathological classification system 
Up to 2010, the terminology for histopathological lesions in diabetic nephropathy was variable. 
The new classification launched in 2010 (Thijs W, 2010) distinguishes four classes, essentially 
characterized by the absence of histological lesions (class I), mesangial changes (class II), 
nodular lesions (class III), or a predominance of global glomerulosclerosis (class IV). 
www.intechopen.com
 
Diabetic Glomerulopathy 
 
345 
 
Table 1. Histological classification of Diabetic glomerulopathy 
7.1.1 Class I: Glomerular basement membrane thickening 
The biopsy specimen shows no or only mild, nonspecific changes by light microscopy that 
do not meet the criteria of classes II through IV. By direct measurements with EM the 
glomerular basement membrane (GBM) on average is thicker than 430 nm in males 9 years 
and older and thicker than 395 nm in females. These cutoff levels are based on a deviation 
from normal GBM thickness plus 2 standard deviations as recently determined. Light 
microscopic changes in the GBM and epithelial foot process effacement by EM have no 
influence on the classification.  
Class I incorporates cases with certain degree of chronic and other reactive changes (e.g., 
changes of arterionephrosclerosis, ischemic type changes, or interstitial fibrosis). Diagnosing 
DN in cases without characteristic light microscopic glomerular lesions may be difficult, 
especially when a thicker GBM is also seen with aging or hypertension. The presence of 
arteriolar hyalinosis may be helpful in these cases, although it is not a prerequisite. 
GBM thickening is a characteristic early change in type 1 and type 2 DN and increases with 
duration of disease. GBM thickening is a consequence of extracellular matrix accumulation, 
with increased deposition of normal extracellular matrix components such as collagen types 
IV and VI, laminin, and fibronectin. Such accumulations result from increased production of 
these proteins, their decreased degradation, or a combination of the two. GBM thickening 
may already be present in type 1 diabetes patients who are normoalbuminuric. GBM 
thickening has even been described as a “prediabetic” lesion: In patients with proteinuria 
and isolated GBM thickening but without overt diabetes, 20% were positive on a blood test 
for diabetes at the time of biopsy, whereas 44% were diagnosed with diabetes at 6 months, 
and 70% at 2 years after the biopsy was taken. Long-term glucose control and urinary 
albumin excretion (UAE) correlate strongly with basement membrane thickness. 
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7.1.2 Class II: Mesangial expansion, mild (IIa) or severe (IIb) 
Class II encompasses those patients classified with mild or severe mesangial expansion but 
not meeting inclusion criteria for class III or IV and is analogous to the previously used term 
“diffuse diabetic glomerulosclerosis.” Mesangial expansion is defined as an increase in 
extracellular material in the mesangium such that the width of the interspace exceeds two 
mesangial cell nuclei in at least two glomerular lobules. The difference between mild and 
severe mesangial expansion is based on whether the expanded mesangial area is smaller or 
larger than the mean area of a capillary lumen. If severe mesangial expansion is seen in 
more than 25% of the total mesangium observed throughout the biopsy, the biopsy is 
classified as IIb. If this is not the case, but at least mild mesangial expansion is seen in more 
than 25% of the total mesangium, the biopsy is classified as IIa. 
Expansion of cellular and matrix components in the mesangium is a hallmark of type 1 and 
type 2 DN. It can be detected in some patients within a few years after the onset of type 1 
diabetes. When the mesangium expands, it restricts and distorts glomerular capillaries and 
diminishes the capillary filtration surface.  
Various indices have been proposed to describe the amount of mesangial expansion in 
DN. Mauer et al. define mesangial expansion by mesangial fractional volume or volume 
density (Vv), defined as the fraction or percentage of the cross-sectional area of the 
glomerular tuft made up by mesangium, expressed in the formula: Vv (mes/glom). Using 
this formula, many correlations have been made between mesangial expansion and 
clinical parameters of DN, particularly showing highly inverse correlations exist between 
Vv (mes/glom) and GFR. There is also a relationship between Vv (mes/glom) and UAE 
and blood pressure.  
Another index to express mesangial expansion is the so-called “index of mesangial 
expansion” (IME) for DN. The IME is determined by a semiquantitative estimate of the 
width of mesangial zones in each glomerulus: grade 0 is normal, 1 is twice normal thickness, 
2 is three times normal thickness, and so forth; half grades can also be assigned. The mean of 
the grades for each glomerulus for IME can thus be determined from a single biopsy. The 
IME closely correlates with the Vv (mes/glom).  
In other classifications, mesangial expansion is defined in more practical ways, such as in 
the new classification for IgA nephropathy in which it is defined as an increase in the 
extracellular material in the mesangium such that the width of the interspace exceeds two 
mesangial cell nuclei in at least two glomerular lobules. 
7.1.3 Class III: Nodular sclerosis (Kimmelstiel–Wilson lesions) 
If at least one convincing Kimmelstiel–Wilson lesion is found and the biopsy specimen does 
not have more than 50% global glomerulosclerosis it is classified as class III. Kimmelstiel–
Wilson lesions appear in type 1 and type 2 diabetes (only one-third of microalbuminuric 
type 2 diabetic patients had them) as focal, lobular, round to oval mesangial lesions with an 
acellular, hyaline/matrix core, rounded peripherally by sparse, crescent-shaped mesangial 
nuclei. Compared to type 1 diabetes, type 2 diabetes  
Paul Kimmelstiel and Clifford Wilson first described nodular lesions in glomeruli from eight 
maturity-onset diabetes patients in 1936. According to Cameron, they barely noted the 
association with diabetes, and it was Arthur Allen who clarified the association in 105 
patients with diabetes in 1941. Nodular sclerotic lesions may also occur in the absence of DN 
that are clinically related to hypertension, smoking, hypercholesterolemia, and extrarenal 
vascular disease. 
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Fig. 10. Representative examples of the morphologic lesions in DN: 
(A) Glomerulus showing only mild ischemic changes, with splitting of Bowman’s capsule. 
No clear mesangial alteration.  
(B) EM of this glomerulus: the mean width of the GBM was 671 nm (mean taken over 55 
random measurements). EM provides the evidence for classifying the biopsy with only mild 
light microscopic changes into class I.  
(C, D) Class II glomeruli with mild and moderate mesangial expansion, respectively. In 
panel C, the mesangial expansion does not exceed the mean area of a capillary lumen (IIa), 
whereas in panel D it does (IIb).  
(E, F) In panel F is a class III Kimmelstiel–Wilson lesion. The lesion in panel E is not a 
convincing Kimmelstiel–Wilson lesion, therefore (on the basis of the findings in this 
glomerulus) the finding is consistent with class IIb. For the purpose of the classification, at 
least one convincing Kimmelstiel–Wilson (as in panel F) needs to be present.  
In panel H, signs of class IV DN consist of hyalinosis of the glomerular vascular pole and a 
remnant of a Kimmelstiel–Wilson lesion on the opposite site of the pole.  
Panel G is an example of glomerulosclerosis that does not reveal its cause (glomerulus from 
the same biopsy as panel H).  
For the purpose of the classification, signs of DN should be histopathologically or clinically 
present to classify a biopsy with global glomerulosclerosis in > 50% of glomeruli as class IV 
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It is claimed that in the initial stage of developing nodular sclerotic lesions in DN, two 
important processes take place: lytic changes in the mesangial area called mesangiolysis and 
detachment of endothelial cells from the GBM. Exactly how these two processes relate 
remains uncertain. Paueksakon et al. detected fragmented red blood cells in Kimmelstiel–
Wilson lesions, which supports the theory that microvascular injury contributes to the 
pathogenesis of these lesions. Dissociation of endothelial cells may disrupt the connections 
between the mesangial area and the GBM. This process precedes expansion of the 
Kimmelstiel–Wilson lesion. These lesions consist of an accumulation of mesangial matrix 
with collagen fibrils, small lipid particles, and cellular debris. 
A completely developed Kimmelstiel–Wilson lesion destroys the normal structure of 
glomerular tuft with a decrease in mesangial cells, especially in the central area. In 1992, a 
graphic method of analysis of the position of Kimmelstiel–Wilson lesions demonstrated the 
nodules were distributed in a horseshoe-shaped area corresponding to the peripheral or 
intralobular mesangium, excluding the possibility of hyperfiltration as being their main 
cause of development. 
The presence of at least one Kimmelstiel–Wilson lesion associates with longer duration of 
diabetes and less favorable clinical parameters. In a study of 36 patients with type 2 
diabetes, patients with Kimmelstiel–Wilson lesions had more severe overall retinopathy and 
higher serum creatinine concentrations than those with mesangial lesions alone. In a study 
of 124 Chinese patients with type 2 diabetes, patients with at least one Kimmelstiel–Wilson 
lesion had relatively long duration of diabetes mellitus, a poor prognosis, and frequent 
evidence of diabetic retinopathy. Kimmelstiel–Wilson lesions are often found in 
combination with mesangial expansion. The occurrence of Kimmelstiel– Wilson lesions is 
widely considered transitional from an early or moderately advanced stage to a 
progressively more advanced stage of disease. 
7.1.4 Class IV: Advanced diabetic glomerulosclerosis 
Class IV implies advanced DN with more than 50% global glomerulosclerosis in which there 
is clinical or pathologic evidence that the sclerosis is attributable to DN. Glomerulosclerosis 
in DN is the end point of multifactorial mechanisms that lead to excessive accumulation of 
extracellular matrix proteins such as collagen types I, III, and IV and fibronectin in the 
mesangial space, which through stages of mesangial expansion and development of 
Kimmelstiel–Wilson lesions finally result in glomerulosclerosis. The clustering of sclerotic 
lesions in columns perpendicular to the kidney surface suggests that vascular factors 
relating to the interlobular arteries also contribute.  
8. Tubulointerstitial lesions, vascular lesions and nondiabetic glomerular 
lesions 
8.1 Tubular lesions 
Concomitant tubular basement membrane thickening of nonatrophic tubules is apparent 
from the development of class II glomerular diabetic lesions and becomes more conspicuous 
in class III and IV, which is best seen in PAS or silver stains. Interstitial fibrosis and tubular 
atrophy (IFTA) follow glomerular changes in type 1 DN that ultimately lead to ESRD. A 
score of 0 is assigned when the biopsy specimen shows no IFTA, a score of 1 is assigned 
when less than 25% IFTA is present, a score of 2 is assigned when at least 25% but less than 
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50% of the biopsy has IFTA, and finally, a score of 3 is assigned when at least 50% IFTA is 
present, which is similar to the scoring in the recently published classification of IgA 
nephropathy. 
Presence of mononuclear cells in the interstitium is a widely recognized finding in DN. 
Inflammatory interstitial infiltrates comprise T lymphocytes and macrophages. A score of 0 
is assigned if interstitial infiltrates are absent, 1 if they only occur around atrophic tubules, 
and 2 if the inflammatory infiltrate is also in other areas than around atrophic tubules. 
8.2 Vascular lesions 
According to Stout et al., hyalinosis of the efferent arteriole is relatively specific for DN, but 
hyalinosis of the afferent arteriole occurs in numerous other settings. Chronic cyclosporine 
nephropathy is a typical example in which arteriolar hyalinosis occurs outside DN. Tracy et 
al. also report the presence of arteriolar hyalinosis in kidneys of young patients with 
coronary heart disease. Efferent arteriolar hyalinosis is an important lesion by which DN is 
distinguished from hypertensive nephropathy. However, most studies relate arteriolar 
hyalinosis to clinical parameters, not distinguishing between efferent and afferent arterioles, 
showing clear correlations with UAE and disease progression.  
In addition to characteristic arteriolar hyalinosis, relatively nonspecific arteriosclerosis may 
be present in the biopsy specimen. Bohle and colleagues found increases in vascular disease 
associate with more severe glomerular disease. Osterby et al. use a so-called “matrix to 
media ratio” to investigate the role of arteriosclerosis and find this ratio is increased in 
patients with microalbuminuria, suggesting that arteriolar matrix accumulation occurs early 
in the course of DN. By assessing the most severely affected artery in the biopsy and assign 
a score of 0 if no intimal thickening is present, 1 if intimal thickening is less than the 
thickness of the media, and 2 if intimal thickening is more than the thickness of the media. 
Isolated or significant medial thickness may be associated with concurrent hypertension. 
9. Other glomerular lesions 
In 1994, Stout et al. defined “insudative lesions” as consisting of intramural accumulations 
of presumably imbibed plasma proteins and lipids within renal arterioles, glomerular 
capillaries, Bowman’s capsule, or proximal convoluted tubules. Insudative lesions in 
Bowman’s capsule are called capsular drop lesions, and in afferent and efferent arterioles 
they are called hyalinized afferent and efferent arterioles. In glomerular capillaries they are 
called fibrin cap lesions, although this term is considered obsolete and moreover is 
amisnomer because the lesion does not contain fibrin; we prefer the term hyalinosis for 
these lesions. 
Capsular drops are mainly located between the parietal epithelium and Bowman’s capsule 
of the glomerulus. Capsular drops are prevalent in advanced DN and associate with disease 
progression. The common belief, reviewed by Alsaad et al., is that capsular drops are 
specific but not entirely pathognomonic of DN. Stout et al. report a prevalence of capsular 
drops in 5.3% of biopsies without diabetes. However, finding a capsular drop in a biopsy 
can help distinguish DN from other causes of glomerulosclerosis.  
By light microscopy, glomerular hyalinosis describes the same staining characteristics as the 
capsular drop lesion but it occupies the capillary lumen instead of being attached to 
Bowman’s capsule. This lesion is not a specific finding in DN, because similar lesions are 
recognized in focal glomerulosclerosis, arterionephrosclerosis, and lupus nephritis. 
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Table 2. Interstitial and vascular lesions of DN 
Finally, there is increasing recognition of abnormalities in the glomerulotubular junctions 
with focal adhesions called “tip lesions” and atrophic tubules with no observable 
glomerular opening (so-called “atubular glomeruli”). These lesions are typically found in 
more advanced stages of nephropathy associated with overt proteinuria. 
One of the important questions that need to be validated is whether the new classification 
system, which makes no distinction between patients with type 1 and type 2 diabetes, is 
helpful for clinicians. Type 2 diabetes has more heterogenous clinical course with more 
heterogenous lesions. Type 2 diabetes also has different response towards treatments, and 
different relationship between diabetic nephropathy and retinopathy. In a study that 
published by Osterby R, Gall MA, Schmitz A, et al in 1993, virtually all patients with type 1 
diabetes with overt nephropathy have retinopathy, whereas less than 50% of patients with 
type 2 diabetes and diabetic nephropathy have diabetic retinopathy. These figures may have 
been altered somewhat in the course of time. In 2010, Pedro et al. studied the prevalence and 
relationship between diabetic nephropathy and retinopathy in a population-based 
transversal study in northeastern Spain including 8187 type 2 and 488 type 1 diabetes 
patients. They distinguished between patients with microalbuminuria and those with overt 
nephropathy. The relationship between microalbuminuria and diabetic retinopathy was 
different between the types of diabetes, but the relationship between overt nephropathy and 
diabetic retinopathy was similar in both types. Overt nephropathy, in this study, was a risk 
factor for diabetic retinopathy in both types. 
10. Biomarker studies 
A number of studies reported on biomarkers in either plasma or urine for diabetic 
nephropathy, particularly in relation to type 2 diabetes. A group from Denmark reported on 
transthyretin, apolipoprotein A1, apolipoprotein C1, and cystatin C as promising 
biomarkers for diabetic nephropathy in the plasma of patients with type 1 diabetes 
(Overgaard AJ 2010). Proteomic analysis of plasma from a cross-sectional cohort of 123 type 
1 diabetic patients previously diagnosed as normoalbuminuric microalbuminuric, or 
www.intechopen.com
 
Diabetic Glomerulopathy 
 
351 
macroalbuminuric, gave rise to 290 peaks clusters. Independent component analysis 
identified 16 candidate peaks that contributed significantly in their respective components 
with high stability and ability to separate the groups. Four of the peaks were identified as 
transthyretin, apolipoprotein A1, apolipoprotein C1, and cystatin.  
Soluble CD40 ligand derived from platelets and mediating atherothrombosis, was shown to 
be elevated in type 1 diabetes patients with diabetic nephropathy in comparison with 
controls. The study was a prospective, observational follow-up study of 443 type 1 diabetes 
patients with diabetic nephropathy and a control group of 421 patients with longstanding 
type 1 diabetes and persistent normoalbuminuria. High levels of sCD40L did not predict 
development of end-stage renal disease (P = 0.85) nor rate of decline in glomerular filtration 
rate (GFR) (Lajer M 2010). 
There were several studies on biomarkers in type 2 diabetes giving rise to a number of 
new markers. A group from China reported an independent association between plasma 
levels of osteopontin and the presence and severity of diabetic nephropathy in type 2 
diabetes (Yan X 2010). In another study on type 2 diabetes, plasma levels of 
methylglyoxal, a side-product of many metabolic pathways, was found to be higher in 
patients with diabetic nephropathy than in those without and, furthermore, were shown 
to correlate with the urinary albumin: creatinine ratio (Lu J 2011). Fibroblast growth factor 
23 (FGF-23), previously reported as a marker for outcome in chronic kidney disease in 
general, was found to be predictive of renal outcome in type 2 diabetes patients with 
macroalbuminuric nephropathy (Alkhalaf A, 2010). At baseline, serum FGF- 23 showed a 
significant association with serum creatinine and proteinuria. FGF-23 was an independent 
predictor of the primary outcome in this study, defined as death, doubling of serum 
creatinine, and/or dialysis need. The moderate consistency observed between biomarkers 
reported in different studies is puzzling, which is probably due to different technologies 
used and the lack of statistical power in some studies resulting in the reporting of 
artifacts. Also the distinction between those patients with and without diabetic 
nephropathy in most of these studies is not proven by biopsy. 
It is evident that a huge amount of effort is being put into how to identify diabetic 
nephropathy in patients with diabetes without being invasive, that is, without taking a renal 
biopsy, both in clinical practice and clinical research studies. A drawback in most of these 
biomarker studies pursuing this aim is that no renal biopsy was taken to determine the 
presence and severity of diabetic nephropathy in the diabetic patients in the first place. 
Virtually all studies rely on clinical parameters, mostly expressed as the amount of 
albuminuria, for the diagnosis of diabetic nephropathy. How reliable is this? Chronic renal 
insufficiency and/or proteinuria especially in type 2 diabetes may stem from chronic renal 
disease other than classic diabetic nephropathy. In a recent retrospective study of 69 patients 
with type 2 diabetes with renal biopsies, 52% had non diabetes-related nephropathy (Mou S, 
2010). Selection bias most likely plays a role in these data, as renal biopsies are typically 
performed in these patients if co-morbidity is suspected. It remains, however, most likely 
that some of the patients included in the biomarker studies were unrightfully given the 
diagnosis of diabetic nephropathy, and it is uncertain how important this contamination of 
the data is for the study outcomes. Only one marker study in 2010 was found that did 
incorporate renal biopsy findings and interestingly, in this study, a classification model was 
able to reliably differentiate diabetic nephropathy from nondiabetic chronic kidney disease 
(Papale M 2010). Among the best predictors of this classification model were ubiquitin and b 
2-microglobulin. 
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There are probably also a considerable proportion of patients without albuminuria who are 
at the beginning stages of diabetic nephropathy. These patients are unrightfully diagnosed 
as not having diabetic nephropathy. Interesting in this light was the 2010 study by Nielsen 
et al., which evaluated the new marker of tubulointerstitial damage kidney injury molecule 
1 (KIM-1) in type 1 diabetes patients with either normoalbuminuria, microalbuminuria, or 
macroalbuminuria in comparison with normal controls. Urine KIM1 was elevated in all type 
1 diabetes patients in comparison with the normal controls and irrespective of the presence 
of albuminuria. Thus, normoalbuminuric patients with type 1 diabetes also had elevated 
urine KIM1. It was therefore concluded that tubular damage may be present at an early 
stage in all patients, the so-called ‘tubular phase’ of diabetic nephropathy. Whether or not 
this means that in fact all patients with type 1 diabetes have a latent form of diabetic 
nephropathy remained undiscussed, but that would be an interesting hypothesis. Another 
study that investigated urinary changes in non-overt diabetic nephropathy in type 2 
diabetes came from Japan (Araki S,2010). This study included 254 patients with type 2 
diabetes of whom 185 were normoalbuminuric and 69 had microalbuminuria. At baseline, 
urinary type IV collagen levels. were higher in patients with microalbuminuria. During a 
follow-up study with a median duration of 8 years, the level of urinary type IV collagen 
inversely correlated with the annual decline in estimated GFR, whereas overt proteinuria 
did not appear in a majority of patients. Two studies from Malaysia gave similar results, 
with type IV collagen levels correlating with the amount of urinary albumin in 30 type 2 
diabetes patients at baseline Sthaneshwar P, 2010), but also with subsequent GFR change 
(Katavetin P 2010). Also in New Zealand, urinary collagen IV was studied in diabetes: spot 
urine samples from 457 unselected patients attending a hospital diabetes clinic were 
analyzed for albumin, creatinine, and a number of biomarkers including collagen IV 
(Cawood TJ, 2010). The proportion of patients with abnormal collagen IV increased from 26, 
58, and 65%, respectively, across the normoalbuminuria, microalbuminuria, and 
macroalbuminuria groups. The authors conclude that longitudinal studies are now required 
to assess whether these biomarkers can detect early renal disease with greater specificity 
and sensitivity than the albumin: creatinine ratio. Including histopathological findings in 
these types of studies would certainly make a great contribution to our better understanding 
of the mechanism leading to diabetic nephropathy. 
11. Treatment 
Interventions that have been found useful in preventing or retarding the progression of DN 
include  
 Strict glycemic control 
 Strict blood pressure control 
 Cessation of smoking 
 Control of hyperlipidemia and  
 Restriction of protein intake.  
12. Strict glycemic control  
Hyperglycemia is an important risk factor for development of microalbuminuria, 
progression of established microalbuminuria to macroalbuminuria and impaired glomerular 
filtration rate (GFR). Additional risk factors for microalbuminuria include older age, male 
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sex, long duration of diabetes, smoking, obesity, elevated blood pressure, and genetic 
predisposition. (de Boer IH 2011) 
Studies have shown that strict glycemic control delays the development of 
microalbuminuria, stabilizes or reduces protein excretion in patients with microalbuminuria 
and overt proteinuria, and slows the rate of progression to chronic renal failure. The 
Diabetes Control and Complications Trial (DCCT) compared conventional with intensive 
glycemic management in 1,441 type-I diabetic patients. This study proved that intensive 
treatment reduced the risks of retinopathy, nephropathy, and neuropathy by 35% to 90% 
compared with conventional treatment. The absolute risks of retinopathy and nephropathy 
were proportional to the mean glycosylated hemoglobin (HbA1c) level over the follow-up 
period preceding each event. Intensive treatment was most effective when begun early, 
before complications were detectable. These risk reductions were achieved at a median 
HbA1c level difference of 9.1% for conventional treatment versus 7.3% for intensive 
treatment. ((The DCCT/EDIC Research Group 2000, The DCCT/EDIC Research Group 
2002)) In the combined cohorts, intensive treatment reduced the development of 
microalbuminuria and clinical albuminuria by 39% and 56%, respectively. The benefits of 
intensive therapy were also long-lasting and persisted beyond the period of shortest 
intervention. (The DCCT/EDIC Research Group 2000, The DCCT/EDIC Research Group 
2002) Thus, intensive treatment should be started as soon as possible safely after the onset of 
type 1 diabetes mellitus and maintained thereafter, aiming for a practicable target HbA1c 
level of 7.0% or less. (Writing Team for the Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications Research Group 2002). 
These findings suggest that hyperglycemia has long-term chronic effects on the underlying 
pathophysiology of microvascular complications. It takes time for improvements in control to 
negate the long lasting effects of prior prolonged hyperglycemia, and once the biological 
effects of prolonged improved control are manifest, the benefits are long lasting. However, 
using the current intensive treatment regimen led to a 3-fold increase in severe hypoglycemic 
events and to excess weight gain in the DCCT. (DCCT/EDIC research group 2002) 
Efforts need to be made to eliminate preventable severe hypoglycemic episodes that result 
from unsafe patient behavior and decisions, and to avoid inordinate weight gain. Irregular 
food intake, failure to check blood glucose before planned or unplanned vigorous exercise 
or before operating a motor vehicle, and excess alcohol ingestion have been identified as risk 
factors for hypoglycemia and serious complications and must be scrupulously avoided. 
Mealtime bolus doses of rapid acting insulin must be based on the pre-injection blood 
glucose level, the anticipated amount of carbohydrate intake and upcoming exercise. 
Thorough diabetes education and its regular reinforcement should be provided by diabetes 
nurse and dietitian educators. These professionals can negotiate individualized care plans 
with patients, give them training in self-management, and provide stimulation, motivation, 
and positive reinforcement for good self-care behavior, such as frequent self blood glucose 
monitoring and regular eating habits. While these measures can interfere with patients’ 
lifestyles, they are the current price that must be paid to delay or reduce the risk of 
microvascular complications. (DCCT/EDIC research group 2002) 
13. Blood pressure control  
Long term and aggressive antihypertensive treatment induces a progressive reduction in the 
rate of decline in kidney function. Thus, this modality of treatment can postpone renal 
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insufficiency in patients with DN. Both systolic and diastolic hypertension markedly 
accelerate the progression of DN, and aggressive antihypertensive management has been 
shown to decrease the rate of fall of glomerular filtration rate, increase the median life 
expectancy, and reduce the need for dialysis and transplantation.  
The primary goal of therapy for non-pregnant patients with DM older than 18 years is to 
achieve a blood pressure less than 130/80 mmHg for patients with proteinuria <1 g/day, and 
less than 125/75 mmHg for patients with >1 g/day of proteinuria. Angiotensin converting 
enzyme (ACE) inhibitors and ARBs are recommended as first-line antihypertensive therapy 
for patients with type-I and type-2 DM. Other agents that can be used include Beta blockers, 
calcium channel blockers, and diuretics. (American Diabetes Association 2003, Ayodele OE 
2004).  
Persistent clinical proteinuria is closely associated with the presence of hypertension in 
IDDM patients. In NIDDM patients the risk of developing clinical proteinuria is increased 
more than twofold in patients with blood pressure > 165/95 mm Hg compared to those with 
lower blood pressure after adjusting for age, sex and duration of diabetes. Moreover, in both 
insulin-dependent and non-insulin-dependent diabetes, the age adjusted total mortality rate 
is greatly increased in those patients with proteinuria or hypertension (Earle K 1994). 
Prospective studies have shown that normoalbuminuric patients who progress to 
microalbuminuria have higher blood pressures (albeit within the normal range) than those 
who persistently remain normoalbuminuric. Parents of insulin-dependent diabetic patients 
with nephropathy have a higher prevalence of hypertension and cardiovascular disease 
compared to patients without nephropathy (Earle K 1994). 
ACE Inhibition versus Angiotensin II (Ang II) receptor type 1 blockade in the Renin-
Angiotensin System (RAS). RAS is one of the most important physiological regulators of 
renal function. ACE inhibitors selectively dilate efferent arterioles. This decreases the arterial 
pressure and in turn reduces glomerular capillary pressure. In addition, Ang II causes 
mesangial cell growth and matrix production. Numerous animal studies and clinical trials 
have shown that ACE inhibitors significantly reduce the loss of kidney function in DN. They 
prevent progression of microalbuminuria to overt proteinuria and several studies evaluated 
the effect of ACE inhibitor on development and progression of DN.  
The landmark study by Lewis et al. [1993], examined the effect of captopril on the 
progression of DN in patients with type 1 DM (Lewis, EJ 1993). This was measured as the 
rate of decline in creatinine clearance and the combined end points of dialysis, 
transplantation, and death. Treatment with captopril was associated with 48% risk reduction 
for doubling the serum creatinine as compared to placebo. The results of this study were 
subsequently confirmed by North American Microalbuminuria Study Group and EUCLID 
study group (EUCLID Study Group 1997, Laffel LM 1995). They extended the observation 
by showing a protective effect of ACE inhibitors in patients with a variety of renal diseases, 
including glomerulopathies, interstitial nephritis, nephrosclerosis, and DN. The exception 
was polycystic kidney disease. Importantly, the protective effect of ACE inhibition was 
independent of the severity of renal insufficiency. (Lewis, EJ 1993, Brown N 1998) 
The MICRO-HOPE (Heart Outcomes Prevention Evaluation) studied the benefit of ramipril 
in type 2 diabetics. The diabetes sub-study of the Heart Outcomes Prevention Evaluation 
study showed ramipril reduced the risk of overt nephropathy by 24%. Moreover, ramipril 
reduced urinary albumin excretion at 1 year and at the end of the study. Thus, ACE 
inhibitors have also been shown to be renoprotective in patients with type 2 DM. (Heart 
Outcomes Prevention Evaluation Study Investigators 2000) 
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Two studies, Irbesartan in Patients with Diabetes and Microalbuminuria (IRMA-2) and 
Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study examined the effect of 
ARB’s in diabetic patients with microalbuminuria, but without overt DN (Parving HH 2001, 
Barnett A 2006). It is well known that, in patients with type 2 DM presence of 
microalbuminuria increases the risk of developing DN 10 to 20 times. IRMA-2 study showed 
that irbesartan significantly reduced the rate of progression of microalbuminuria to overt 
DN in patients with type 2 diabetes. Furthermore, the study discovered that irbesartan was 
associated with significantly more common restoration of normoalbuminuria as compared 
to standard therapy. All these effects were achieved independent of the systemic blood 
pressure. The more recent DETAIL study compared the renoprotective effects of ACE 
inhibitor enalapril and ARB telmisartan. In this head-to-head comparison the authors 
showed that both treatments were equally effective in preventing the progression of renal 
dysfunction, measured as decline in the GFR. Reduction of Endpoints in NIDDM with 
Angiotensin II Antagonist Losartan (RENAAL) study (Brenner BM 2001) showed that 
treatment with losartan was associated with a 25% decrease in the risk for doubling serum 
creatinine level. The risk of developing ESRD was also reduced by 28%.  
Other individual factors may better define the impact of ACE inhibitors on the progression 
of renal insufficiency. In particular, Rigat et al described an insertion (I) and deletion (D) 
polymorphism in the ACE gene that correlates with ACE activity. ACE levels are highest in 
patients who are homozygous for the ACE D allele and lowest in patients homozygous for 
the ACE I allele (Rigat B 1990). They are intermediate in those who are heterozygous. 
Yoshida et al (Yoshida H 1995) later reported a greater reduction in proteinuria in response 
to ACE inhibition in patients with IgA nephropathy who were homozygous for the D allele. 
In contrast to this, other investigators have suggested a worse response to therapy in 
patients who carry the D allele (Parving HH 1996). Obviously, large-scale studies are needed 
to define the impact of genetic factors on the renal protective effects of ACE inhibition.  
There are studies suggesting that dual blockade of renin-angiotensin system using a 
combination of ACE inhibitor and an ARB in patients with nephropathy is superior to the 
use of either drug alone. (Ayodele OE 2004, Mogensen CE 2000, Rosner MH 2003).  
The antiproteinuric effects of inhibitors of the renin angiotensin system are increased by 
sodium restriction and by concomitant administration of diuretics or non-dihydropyridine 
calcium channel blockers. (American Diabetes Association 2002, Ayodele OE 2004, Arauz-
Pacheco C 2002). 
In the United Kingdom Prospective Diabetes Study, atenolol showed beneficial effects 
comparable to captopril on diabetes-related mortality and microvascular complications in 
patients with type-2 diabetes. (United Kingdom Prospective Diabetes Group 1998) Beta-
blockers have been shown to reduce mortality following myocardial infarction, and the 
absolute benefit of a given relative reduction is greater in diabetics compared to 
nondiabetics due to higher mortality from myocardial infarction in patients with diabetes. 
(Ayodele OE 2004) The nondihydropyridine calcium channel blockers have been shown to 
lower protein excretion in patients with diabetes. (Bakris GL 1990 and 1997) Their 
antiproteinuric effect may be due to reduction in intraglomerular pressure, reduction in 
glomerular hypertrophy, and improved glomerular size. The dihydropyridine calcium 
channel blockers have a variable effect on protein excretion ranging from increased 
protein excretion to no effect to a fall in protein excretion in various studies. (Melbourne 
Diabetic Nephropathy Study Group 1991, Vellussi M 1996, Salako BL 2002, Rosssing P, 
1997) 
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14. Protein restriction  
The role of dietary protein restriction in CKD is best described as controversial. However, 
restriction of protein (0.6 g/kg body weight per day) and phosphorus (0.5 to 1 g per day) were 
shown to reduce the decline in GFR, lower blood pressure, and stabilize renal function 
compared with higher intakes. This was suggested by a randomized trial involving patients 
with type-I DM and overt DN. In addition, another study showed that restriction of protein 
intake to 0.8 g/kg body weight per day reduced the rate of progression to ESRD in patients 
with type-I diabetes. The National Kidney Foundation recommends that patients with GFR <29 
mL/min per m2 should have a daily protein intake of 0.6 g/kg body weight. More recently, a 4-
year randomized controlled trial in 82 patients with type 1 diabetes with progressive DN 
showed that a moderately low–protein diet (0.9 g · kg−1 · day−1) reduced the risk of ESRD or 
death by 76%, although no effect on GFR decline was observed (Hansen HP, 2002) 
A prospective, randomized controlled trial in patients with type 1 diabetes suffering from 
progressive diabetic nephropathy demonstrated beneficial effect of moderate restriction in 
dietary protein on the development of ESRD or death. The beneficial effect of protein 
restriction appeared within the first year, and persisted with continued treatment, as also 
has been demonstrated in non-diabetic nephropathies suggesting that type 1 diabetic 
patients with progressive diabetic nephropathy are highly sensitive to dietary protein 
restriction (Hansen HP, 2002). 
The mechanisms by which a low-protein diet may reduce progression of DN are still 
unknown, but might be related to improved lipid profile and/or glomerular 
hemodynamics. (Jorge L, 2005) Since diabetic patients have other restrictions to the diet, this 
may reduce compliance to an additional low-protein diet, although better compliance can be 
obtained by applying much more intensive dietary counseling (Hansen HP, 2002) 
15. Cessation of smoking 
Smoking has been shown in many previous studies to effect diabetic complications. 
Cessation of smoking alone may reduce the risk of progression by 30% in patients with type-
2 diabetes. (Ritz E, 2000) Recent studies demonstrated that smokers have increased systolic 
blood pressures and proteinuria amongst diabetics with nephropathy (Sawicki, PT 1996) 
More recent work by Chihuran et al has shown that renal function declines faster in smokers 
than nonsmokers with type 2 DN undergoing treatment to improve blood pressure 
including ACE inhibitors. Also, loss of renal function is slower in those who stopped 
smoking. Cigarette smoking remains a risk factor for renal function decline in type 2 DN 
despite currently recommended therapy (Chihuran T, 2002)  
16. Hyperlipidemia 
There is suggestion that elevation in lipid levels may contribute to the development of 
glomerulosclerosis in chronic renal failure. (Ravid M, 1995, Krolewski AS, 1994) Studies have 
shown that lipid lowering may have a beneficial effect on renal function. (Lam KSL, 1995) A 
meta-analysis of 13 controlled trials involving a total of 362 subjects, 253 of whom had 
diabetes, showed that statins decreased proteinuria and preserved GFR in patients with 
chronic renal disease. (Fried LF, 2001) Adequately powered randomized controlled trials will 
be needed to determine the role of lipid lowering therapy in retarding the rate of decline in 
kidney function in patients with chronic renal disease secondary to diabetes mellitus. 
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17. Renal replacement therapy 
The renal replacement modalities available for patients with ESRD from diabetes include 
peritoneal dialysis, hemodialysis, and renal transplantation. Various studies have shown 
similar survival in hemodialysis and peritoneal dialysis, though patients are more likely to 
persist with hemodialysis than with peritoneal dialysis. Both hemo- and peritoneal dialysis 
limit social life, leisure, and sexual activity.(Hostetter TH, 1981) Patients with diabetes may 
manifest uremic symptoms at a relatively less-advanced degree of renal insufficiency than 
their nondiabetic counterparts. (Hostetter TH, 1982) 
18. Emerging therapies 
Extensive research is currently underway in this field and some new pathogenic mediators 
for DN have been discovered. These include 
 Renin  
 Advanced Glycosylation end-products [AGE]  
 Protein Kinase C [PKC]  
 Transforming growth factor – Beta 1 [TGF-1]  
 Nitric Oxide [NO]  
 Vascular endothelial growth factor [VEGF]  
 Oxidative stress  
18.1 Direct renin inhibitor – Aliskiren  
Blockade of RAS is a key therapeutic strategy in slowing progression of DN. Interruption of 
the RAS may also be accomplished by blocking the activity of renin. Aliskiren is a direct 
renin inhibitor and thus, decreases angiotensin II and aldosterone levels. Aliskiren is a 
potent antihypertensive and anti proteinuric.  
18.2 Advanced Glycosylation end-products [AGEs]  
The formation of AGEs and their cross-linked products is a phenomenon of normal aging; 
however, it is accelerated in the DM. AGE–cross-linked products accumulate in patients 
with DM and have been implicated in the pathologic process of diabetic complications. 
Several anti-AGE agents have been tested and shown to be renoprotective in experimental 
diabetic animal models. (Thomas MC, 2005)  
Aminoguanidine is the prototype of an AGE formation inhibitor which acts by scavenging 
intermediates in the advanced glycation catalytic process.  
ALT-946 is a more potent and selective AGE formation inhibitor than aminoguanidine. It 
has minimal effects on NO synthesis and appears to have fewer toxic effects, although it has 
not been studied in as much detail.  
Pyridoxamine (PYR) - Pyridoxamine is one of the three natural forms of pyridoxine (vitamin 
B6). It scavenges pathogenic reactive carbonyl species and inhibits the formation of AGEs 
from Amadori compounds. (Voziyan PA, 2002, Chetyrkin SV, 2008)  
18.3 Thiamine  
Experimental studies have suggested that thiamine and benfothiamine (S-benzoylthiamine 
monophosphate), a vitamin B1 derivative, can also prevent or decrease kidney injury. These 
drugs decrease formation of AGE compounds and protein kinase C (PKC) activity in DN.  
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AGE Breakers - This group of compounds decreases AGE accumulation by breaking the 
glycation cross-links.  
AGE Receptor Antagonists - AGEs mediate their effects both directly and indirectly through 
receptor-dependent mechanisms. They bind to the transmembrane receptor for AGE 
(RAGE) and prevent the development of diabetic microvascular complications. (Bierhaus A 
2005, Wendt T, 2003) Thus, RAGE is a potential target to prevent AGE effects.  
18.4 Pentoxifylline  
Pentoxifylline (PTF) is a methylxanthine derivative with hemorheological properties that 
has favorable effects on microcirculatory blood flow. In vivo, it also functions as a 
phosphodiesterase inhibitor. (Navarro J.F., 1999)  
18.5 Protein Kinase C inhibitors  
Recent studies have identified that activation of PKC initiated by hyperglycemia is 
associated with many vascular abnormalities in retinal, renal, and cardiovascular tissues. 
The blocking of PKC-beta isoforms has been shown to decrease albuminuria, structural 
injury, and TGF-beta expression in animal models of DM. (Koya D, 2000) Ruboxistaurin is 
one such PKC beta inhibitor. 
18.6 Glycosaminoglycans  
Glycosaminoglycans are important determinants of GBM permeability. An emerging body 
of evidence supports the notion that glomerular capillary wall and mesangial alterations in 
DN involve pathobiochemical alterations of glycoproteins in these structures. Heparin and 
sulodexide are examples of this class of drugs. 
18.7 Endothelin receptor antagonists  
DN is associated with enhanced renal synthesis of endothelins. A number of preclinical reports 
suggested that endothelin might be an appropriate target to decrease DM-related albuminuria. 
(Turgut F, 2010) Avosentan (SPP301) is a new orally available endothelin 1 antagonist.  
18.8 Antifibrotic agents and growth factor inhibitors  
Characteristic morphologic lesions of DN include glomerular hypertrophy, thickening of the 
basement membrane, and mesangial expansion. This leads to glomerulosclerosis, 
tubulointerstitial fibrosis, and, eventually, loss of kidney parenchyma. Several growth factors 
which are normally expressed in the kidney have been implicated in the pathogenesis of DN.  
TGF-β Inhibitors - Pirfenidone (PFD) is a low molecular weight synthetic molecule that 
exerts dramatic antifibrotic properties in cell culture and various animal models of fibrosis. 
SMP-534, another antifibrotic agent is also being studied. Several AGE inhibitors also 
decrease TGF-ǃ levels. (Turgut F,2010, Sugaru E., 2006)  
CTGF Inhibitors - Connective tissue growth factor (CTGF/CCN2) has been associated with 
fibrosis in various tissues including the kidney. It is up-regulated in most models of DN. 
Clinical trials evaluating anti-CTGF ab (FG3019) are underway. 
18.9 Nitric Oxide (NO) modulation  
Abnormalities of renal NO generation have been linked to pathogenesis of renal disease in 
diabetes. NO and / or NO Synthase are targets for drug development for treatment and/or 
prevention of DN. 
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18.10 Vascular endothelial growth factor (VEGF) inhibitors  
VEGF is a main regulator of blood vessel growth and plays an important role in promoting 
endothelial survival and maintaining the microvasculature. Loss of capillaries is strongly 
associated with the progression of CKD to ESRD (Doi K, 2010).  
19. Alternative and complementary therapies for diabetic nephropathy 
19.1 Exercise and Yoga 
The American Diabetes Association recommends a minimum of 30 minutes of moderate-
intensity aerobic physical activity 5 days per week, or vigorous-intensity aerobic physical 
activity for 20 minutes 3 times per week is recommended for healthy adults aged 18 to 65. 
Currently, there is no clinical evidence to suggest that vigorous exercise increases the rate of 
progression of diabetic nephropathy. In fact, some studies have shown that aerobic exercise 
actually decreased urine protein excretion (Gordon LA, 2008). Additionally, it has been 
demonstrated that resistance training may have a beneficial effect on muscle mass, 
nutritional status, functional capacity, and glomerular filtration rate. Therefore, the 
American Diabetes Association feels that there is no need to restrict exercise in patients with 
diabetic nephropathy. A more recent study that examined the effects of Yoga and 
conventional exercise showed findings that suggest better glycemic and blood pressure 
control obtained in type 2 diabetic patients after Hatha yoga than conventional PT exercises 
(Gordon LA, 2008).  
19.2 Life style modifications  
Obesity is often associated with diabetes mellitus and also with nephropathy independent 
of diabetes (often focal sclerosis). However the impact of weight loss in diabetic subjects 
with nephropathy on renal function and proteinuria remains as a subject of intense 
investigation. Short term studies recently reported that weight reduction using dietary 
therapy for 4 weeks resulted in significant reduction in systolic pressure, proteinuria, and 
serum creatinine in obese patients with diabetic nephropathy. (A Saiki, 2005). Longer 
studies involving larger group of patients need to be evaluated to validate such conclusions. 
19.3 Herbal and Food derivatives  
19.3.1 Curcumin  
Curcumin is the active component in Tumeric Rhizomes (Curcuma Long Linn). Curcumin 
has been shown to possess anti-inflammatory, anti-oxidant and antifibrotic properties in 
many tissues, in vivo and in vitro studies. Tikoo et al have shown that curcumin treatment 
prevented the development of DN by significantly lowering blood urea nitrogen and 
plasma creatinine/body weight ratio in diabetic animals. (Tikoo K, 2008) Various biological 
actions of curcumin are mediated by inhibiting cell proliferation (Sikora E, 1997), oxidative 
stress and inflammation (Sharma C, 2006). Several other investigators have also shown that 
the anti-inflammatory property of curcumin can significantly improve kidney function in 
animals with chronic renal failure.  
19.3.2 Cinnamon 
Cinnamon has been known for its antidiabetic effects for some time now. Mishra et al have 
investigated its effects on nephropathy in diabetes in rodent models of type I diabetes. 
Histological studies of the kidney proved the protective effect of cinnamon oil by reducing 
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the glomerular expansion, eradicating hyaline casts, and decreasing the tubular dilatations. 
(Mishra A, 2010). The authors concluded that the volatile oil from cinnamon contains more 
than 98 % cinnamaldehyde and that it confers dose-dependent, significant protection against 
alloxan-induced renal damage. While the mechanism of its action remains unclear, it is 
believed to be mostly due to its antidiabetic and antioxidant effects leading to reduced 
formation of AGEs.  
20. Conclusions  
During the last 3 decades, considerable progress has been made in delaying the progression of 
CKD even as the frequency of DN continues to increase. This is a truly a reflection of the 
advances made in understanding the pathogenesis. As reviewed in this chapter many 
pathogenic cytokines and growth factors have emerged in the recent years that either initiate or 
contribute to the progressive renal injury in diabetes. Current treatment options are still 
suboptimal. However with the rapid strides being made in the field, several new therapeutic 
targets are being recognized and effective treatment strategies being developed. 
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